[go: up one dir, main page]

EA200501159A1 - Интраназальный препарат ротиготина - Google Patents

Интраназальный препарат ротиготина

Info

Publication number
EA200501159A1
EA200501159A1 EA200501159A EA200501159A EA200501159A1 EA 200501159 A1 EA200501159 A1 EA 200501159A1 EA 200501159 A EA200501159 A EA 200501159A EA 200501159 A EA200501159 A EA 200501159A EA 200501159 A1 EA200501159 A1 EA 200501159A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rotigotin
intranasal drug
rotigotine
cyclodextrin
viscosity
Prior art date
Application number
EA200501159A
Other languages
English (en)
Other versions
EA008005B1 (ru
Inventor
Роберт Кремер
Original Assignee
Шварц Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шварц Фарма Аг filed Critical Шварц Фарма Аг
Publication of EA200501159A1 publication Critical patent/EA200501159A1/ru
Publication of EA008005B1 publication Critical patent/EA008005B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение относится к жидкому интраназальному фармацевтическому препарату, содержащему фармацевтически приемлемую соль ротиготина, полученную присоединением кислоты, и α-циклодекстрин, предпочтительно в форме забуференного водного раствора, имеющего вязкость 0,5-1,5 мм/с.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200501159A 2003-12-23 2004-12-22 Интраназальный препарат ротиготина EA008005B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03029680A EP1547592A1 (en) 2003-12-23 2003-12-23 Intranasal formulation of rotigotine
PCT/EP2004/014626 WO2005063236A1 (en) 2003-12-23 2004-12-22 Intranasal formulation of rotigotine

Publications (2)

Publication Number Publication Date
EA200501159A1 true EA200501159A1 (ru) 2006-02-24
EA008005B1 EA008005B1 (ru) 2007-02-27

Family

ID=34530709

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501159A EA008005B1 (ru) 2003-12-23 2004-12-22 Интраназальный препарат ротиготина

Country Status (27)

Country Link
US (1) US7683040B2 (ru)
EP (2) EP1547592A1 (ru)
JP (1) JP4430067B2 (ru)
KR (1) KR100718760B1 (ru)
CN (1) CN100374112C (ru)
AT (1) ATE326961T1 (ru)
AU (1) AU2004308641B2 (ru)
BR (1) BRPI0407845A (ru)
CA (1) CA2516400C (ru)
CY (1) CY1105131T1 (ru)
DE (1) DE602004000982T2 (ru)
DK (1) DK1605932T3 (ru)
EA (1) EA008005B1 (ru)
ES (1) ES2262122T3 (ru)
HR (1) HRP20060240T3 (ru)
IL (1) IL170297A (ru)
IS (1) IS2310B (ru)
MX (1) MXPA05008909A (ru)
NO (1) NO20054018L (ru)
NZ (1) NZ541875A (ru)
PL (1) PL1605932T3 (ru)
PT (1) PT1605932E (ru)
RS (1) RS50534B (ru)
SI (1) SI1605932T1 (ru)
UA (1) UA79196C2 (ru)
WO (1) WO2005063236A1 (ru)
ZA (1) ZA200506550B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
EP1426049B1 (en) 2002-12-02 2005-05-18 Schwarz Pharma Ag Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
RS54235B1 (sr) 2007-11-28 2015-12-31 Ucb Pharma Gmbh Polimorfni oblik rotigotina
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
BR112012017737A8 (pt) 2009-12-22 2018-04-17 Lts Lohmann Therapie Systeme Ag polivinilpirrolidona para a estabilização de uma dispersão sólida da forma não cristalina de rotigotina.
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
WO2013075823A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
CN103768043B (zh) * 2012-10-22 2015-12-09 苏州药明康德新药开发股份有限公司 采用羟丙基-β-环糊精配制四氢化萘类化合物均一稳定溶液的方法
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
ES2694662T3 (es) 2013-07-03 2018-12-26 Lts Lohmann Therapie-Systeme Ag Sistema terapéutico transdérmico con componente electrónico
EP3108245B1 (en) 2014-02-18 2020-07-22 Robert I. Henkin Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
WO2015177204A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
CN110917125B (zh) * 2020-01-02 2022-08-12 安徽中医药大学 一种罗替戈汀鼻用胶束温敏凝胶的制备方法
KR20240134157A (ko) * 2022-01-06 2024-09-06 시라노 테라퓨틱스, 아이엔씨. 파킨슨 치료제의 개선된 코 투여
CN120053353A (zh) * 2024-05-31 2025-05-30 纳索菲德(上海)制药技术有限公司 一种巴氯芬鼻脑递释组合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108991A (en) 1975-06-19 1992-04-28 Whitby Research, Inc. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4992422A (en) 1986-01-31 1991-02-12 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes
US5218113A (en) 1986-01-31 1993-06-08 Whitby Research, Inc. N-substituted thiolactams
JPS63502282A (ja) 1986-01-31 1988-09-01 ホイットビ−・リサ−チ・インコ−ポレ−テッド １−置換アザシクロアルカン類より成る組成物とその用法
US4755535A (en) 1986-04-23 1988-07-05 Nelson Research & Development Co. Compositions comprising 1-substituted azacycloalkenes
US5073544A (en) 1986-08-15 1991-12-17 Whitby, Inc. Transdermal compositions of 1-oxohydrocarbyl-substituted azacyclohexanes
US4902676A (en) 1986-09-29 1990-02-20 Nelson Research & Development Co. Compositions comprising N,N-dialkylalkanamides
DE3868866D1 (de) 1987-11-20 1992-04-09 Erba Carlo Spa Ergolinderivate mit antiparkinsonwirkung.
US5472946A (en) 1988-04-08 1995-12-05 Peck; James V. Transdermal penetration enhancers
US5073844A (en) * 1991-01-11 1991-12-17 The Annlouise Partnership Lighted baggage piece
US6086905A (en) 1991-03-21 2000-07-11 Peck; James V. Topical compositions useful as skin penetration barriers
US5308625A (en) 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US5989586A (en) 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
DK0689438T3 (da) * 1993-03-26 2003-09-29 Franciscus Wilhelmus He Merkus Farmaceutiske præparater til intranasal administration af apomorfin
GB9324018D0 (en) 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
US5771890A (en) 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
CA2193885C (en) 1994-06-24 2003-11-25 Janet Tamada Iontophoretic sampling device and method
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
AUPQ969800A0 (en) 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
ATE251901T1 (de) 2001-05-08 2003-11-15 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches system für die erzielung hoher plasmaspiegel von rotigotin in der therapie von morbus parkinson
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
HU227543B1 (en) 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
BR0309259A (pt) 2002-04-18 2005-02-09 Pharmacia Corp Terapia combinada para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox 2)
CA2503381A1 (en) 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
US20050032873A1 (en) 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
WO2005070428A1 (en) 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
ATE390424T1 (de) 2004-08-02 2008-04-15 Sanol Arznei Schwarz Gmbh Carboxamide des indolizins und seiner aza- und diazaderivate
DE102004054634A1 (de) 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide

Also Published As

Publication number Publication date
EP1605932B1 (en) 2006-05-24
EP1605932A1 (en) 2005-12-21
KR20060040578A (ko) 2006-05-10
PT1605932E (pt) 2006-08-31
NZ541875A (en) 2008-08-29
US7683040B2 (en) 2010-03-23
CN100374112C (zh) 2008-03-12
DE602004000982D1 (de) 2006-06-29
CA2516400C (en) 2009-10-27
AU2004308641B2 (en) 2006-10-26
BRPI0407845A (pt) 2006-02-14
RS50534B (sr) 2010-05-07
DE602004000982T2 (de) 2007-05-10
EP1547592A1 (en) 2005-06-29
DK1605932T3 (da) 2006-09-18
ATE326961T1 (de) 2006-06-15
IS2310B (is) 2007-11-15
MXPA05008909A (es) 2005-10-05
ES2262122T3 (es) 2006-11-16
HRP20060240T3 (hr) 2007-05-31
HK1083596A1 (en) 2006-07-07
KR100718760B1 (ko) 2007-05-15
CY1105131T1 (el) 2009-11-04
JP2006526004A (ja) 2006-11-16
ZA200506550B (en) 2006-05-31
EA008005B1 (ru) 2007-02-27
UA79196C2 (en) 2007-05-25
PL1605932T3 (pl) 2006-09-29
NO20054018L (no) 2005-08-30
IL170297A (en) 2010-06-30
JP4430067B2 (ja) 2010-03-10
AU2004308641A1 (en) 2005-07-14
SI1605932T1 (sl) 2006-08-31
US20070191308A1 (en) 2007-08-16
CA2516400A1 (en) 2005-07-14
CN1777422A (zh) 2006-05-24
WO2005063236A1 (en) 2005-07-14
IS8487A (is) 2006-05-26

Similar Documents

Publication Publication Date Title
EA200501159A1 (ru) Интраназальный препарат ротиготина
EA200400777A1 (ru) Фармацевтические композиции соединения платины
EA200500392A1 (ru) Производные пиримидина и их применение в качестве модуляторов св2
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
EA200300999A1 (ru) Хронотерапевтические дозированные формы
EA200400432A1 (ru) Производные мочевины
EA200970726A1 (ru) Твердый препарат, содержащий алоглиптин и пиоглитазон
HUS1600061I1 (hu) 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-2-pirimidinil]amino]benzonitril
ATE331525T1 (de) Salzformarme polyallylamine
HUP0203773A2 (hu) Epinastintartalmú oldatok
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
ATE357212T1 (de) Wässrige pharmazeutische lösung enthaltend oxymetazolin und/oder xylometazolin
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
EA200101150A1 (ru) Раствор прукалоприда для перорального применения
EA200201232A1 (ru) Производные сульфонамида
NO20050247L (no) Lavmolekylaert oversulfatert polysakkarid
DE60136064D1 (de) Wässrige flüssige preparation von pranoprofen
EA200100802A1 (ru) Применение тианептина при приготовлении лекарственных средств, предназначенных для лечения нейродегенеративных патологий
JP2004010511A5 (ru)
EA200501088A1 (ru) Цетилпиридиниевая соль противоспалительного средства и фармацевтические композиции, содержащие ее
EA200501765A3 (ru) Средство для лечения болезней суставов
EA200401119A1 (ru) Капсулированный препарат

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU